LDS/Medical Tests/Muscle-Specific Kinase (MuSK) Autoantibody

Muscle-Specific Kinase (MuSK) Autoantibody

Myasthenia gravis is an autoimmune disorder of the neuromuscular junction that leads to impaired nerve impulse transmission and defective muscle contraction. Clinically, it presents with dysphagia, ptosis, diplopia, and variable skeletal muscle weakness ranging from mild to severe. At the molecular level, most cases are driven by IgG1 and IgG3 autoantibodies that block or degrade nicotinic acetylcholine receptors (AChRs) at the postsynaptic membrane. In other patients, disease arises from autoantibodies that target muscle-specific kinase (MuSK), a receptor tyrosine kinase critical for clustering and maintaining AChRs at the neuromuscular junction. Disruption of either pathway results in impaired synaptic signaling and the characteristic muscle weakness of myasthenia gravis.

The condition is most often mediated by autoantibodies against the acetylcholine receptor (AChR), detected in the majority of MG patients. However, approximately 10–15% of MG patients are seronegative for anti-AChR antibodies. Among these, nearly one-third test positive for antibodies against muscle-specific kinase (MuSK). MuSK is a receptor tyrosine kinase essential for clustering and maintaining AChR at the postsynaptic membrane of the neuromuscular junction. Autoantibodies targeting MuSK disrupt this process, leading to impaired synaptic signaling. MuSK-MG can present at any age, is more prevalent in female patients, and often differs clinically from AChR-MG, sometimes presenting with bulbar weakness and more severe disease. Importantly, MuSK-MG may mimic amyotrophic lateral sclerosis (ALS), making accurate antibody testing essential for differential diagnosis.

  • As an aid in diagnosing myasthenia gravis
  • Differential diagnosis of AChR myasthenia gravis from MuSK myasthenia gravis
  • Therapy selection and monitoring and disease management

A positive result indicates that myasthenia gravis is likely due to autoantibodies targeting MuSK. This supports a diagnosis of MuSK-positive MG and may inform specific therapeutic approaches, including earlier initiation of immunosuppressive therapy or consideration of monoclonal antibody treatment such as rituximab.

A negative result suggests that anti-MuSK antibodies are not present. In this case, results should be interpreted alongside anti-AChR antibody status. Approximately 6–10% of MG patients are double-seronegative (negative for both AChR and MuSK antibodies). In these patients, testing for antibodies to low-density lipoprotein receptor-related protein 4 (LRP4) may be informative.

< or =0.02 nmol/L

Radioimmunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA)..

Serum (SST).

Stability

  • Ambient: 1-3 days
  • Refrigerated: 5-7 days
  • Frozen: 28 days
Anti-AChR antibodies, anti-LRP4 antibodies, antinuclear antibodies (ANA), creatine kinase, rheumatoid factor.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login